替比夫定联合恩替卡韦对失代偿期乙肝肝硬化患者血清可溶性红细胞补体受体1的影响

Effect of Telbivudine Combined with Entecavir on Serum Soluble Erythrocyte Complement Receptor 1 in Patients with Decompensated Hepatitis B Cirrhosis

目的:探讨替比夫定联合恩替卡韦对失代偿期乙肝肝硬化患者血清可溶性红细胞补体受体1(sCR1)的影响。方法:选取2015年1月-2018年1月本院收治的62例失代偿期乙肝肝硬化患者,按照随机数字表法分为观察组和对照组,每组31例。对照组给予替比夫定治疗,观察组给予替比夫定联合恩替卡韦治疗。比较两组谷丙转氨酶(ALT)、白蛋白(ALB)、总胆红素(TBIL)、Child-Pugh评分、血清sCR1水平、乙肝病毒的脱氧核糖核酸(HBV-DNA)转阴率、乙肝e抗原(HBeAg)转阴率。结果:治疗后,观察组ALT、TBIL均明显低于对照组,ALB明显高于对照组(P<0.05);观察组Child-Pugh评分明显低于对照组(P<0.05);两组HBV-DNA和HbeAg转阴率比较,差异均无统计学意义(P>0.05);观察组血清sCR1明显低于对照组(P<0.05)。结论:替比夫定联合恩替卡韦治疗可降低失代偿期乙肝肝硬化患者血清sCR1水平,改善肝功能,提高乙肝病毒清除率。

Objective: To investigate the effect of Telbivudine combined with Entecavir on serum soluble erythrocyte complement receptor 1(sCR1) in patients with decompensated hepatitis B cirrhosis. Method: A total of 62 patients with decompensated hepatitis B cirrhosis in our hospital from January 2015 to January 2018 were selected and divided into observation group and control group according to random number table method, 31 cases in each group. The control group was treated with Telbivudine, while the observation group was treated with Telbivudine combined with Entecavir. Alanine aminotransferase(ALT), albumin(ALB), total bilirubin(TBIL), Child-Pugh score, serum sCR1 level, HBV DNA negative rate and HBeAg negative rate of two groups were compared. Result: After treatment, ALT and TBIL in the observation group were lower than those in the control group, and ALB was higher than that in the control group(P<0.05). The Child-Pugh score in the observation group was lower than that in the control group(P<0.05). There were no significant differences in HBV-DNA and HBeAg negative conversion rates between two groups(P>0.05). Serum sCR1 in the observation group was lower than that in the control group(P<0.05). Conclusion: Tibivudine combined with Entecavir can reduce the level of sCR1, improve liver function, and increase the clearance rate of hepatitis B virus.